This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.2 (other sphingolipidosis) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | Fabry (-Anderson) disease, Anderson-Fabry disease, α-galactosidase A deficiency, GLA deficiency, glycolipid lipidosis, Angiokeratoma corporis diffusum, Hereditary dystopic lipidosis |
| C. Adult onset | Likelihood of first onset in adulthood: high (especially in heterozygous women and later-onset men) — in classic men it begins with neuropathic pain and angiokeratomas in childhood to adolescence, but cases first presenting in adulthood with cardiac, renal, or stroke symptoms are very common in later-onset (cardiac/renal variant) men and heterozygous women. |
| 1. History | 1898 simultaneous description by Fabry (Germany) and Anderson (UK) → 1947 classification as a lipidosis → 1965 Brady identified α-galactosidase A deficiency → 1967 GLA gene location identified → 2001 first ERT (agalsidase alfa/beta) approved → 2016 migalastat approved. |
| 2. Causes | GLA gene (Xq22.1) variants → α-galactosidase A (α-Gal A) deficiency → lysosomal accumulation of Gb3 (globotriaosylceramide) and lyso-Gb3 → damage to endothelial cells of the kidneys, heart, brain, and skin. |
| 3. Genetics | GLA gene (Xq22.1), X-linked recessive. More than 1,000 pathogenic variants reported. Hemizygous men: classic or later-onset type. Heterozygous women: highly variable phenotype (asymptomatic to severe, male-like). |
| 4. General epidemiology | Traditional estimate: about 1 per 50,000 male births. Newborn screening-based estimate: 1 per 1,500~4,000 (including later-onset type). Occurs worldwide in all ethnic groups. Several hundred patients estimated in Korea. |
| 5. Pathophysiology | α-Gal A deficiency → lysosomal and cytoplasmic accumulation of Gb3 (GL-3) and lyso-Gb3 → damage to vascular endothelial cells, smooth muscle, myocardium, and glomerular cells → oxidative stress, inflammation, fibrosis, thrombosis → renal failure, myocardial hypertrophy, stroke. |
| 6. Symptoms | Neuropathic pain (burning pain in the extremities), angiokeratomas (skin), reduced sweating, corneal opacity, gastrointestinal symptoms. Late: renal failure, left ventricular hypertrophy, heart failure, arrhythmias, stroke, TIA. Women: various moderate symptoms. |
| 7. Signs | Angiokeratomas (lower abdomen, perineum, periumbilical area). Slit lamp: whorled corneal opacity (cornea verticillata). Echocardiography: LVH, non-obstructive hypertrophic cardiomyopathy. Urine: proteinuria, dysmorphic red blood cells, lipid-laden granular cells. MRI: white matter lesions, occipital lobe and thalamic involvement. |
| 8. Screening | DBS α-Gal A enzyme activity (highly sensitive screening in men). Plasma and urine lyso-Gb3 (useful in both men and women). High-risk groups: screening of patients with renal failure, unexplained LVH, or stroke at a young age. Family history-based genetic counseling. |
| 9. Diagnosis | Men: markedly reduced leukocyte α-Gal A activity + GLA variant. Women: α-Gal A may be normal → GLA gene analysis essential. Elevated lyso-Gb3 aids diagnosis. Renal and cardiac biopsy: "zebra bodies" on electron microscopy. |
| 10. Treatment | ERT: agalsidase alfa (Replagal, 0.2 mg/kg every other week) or agalsidase beta (Fabrazyme, 1 mg/kg every other week). Migalastat (Galafold, 123 mg every other day, only for amenable variants). Secondary management of renal, cardiac, neurologic, and stroke complications. |
| 11. Prognosis | Early ERT can preserve renal function, reduce cardiac hypertrophy, and relieve pain. The later treatment is started, the higher the risk of irreversible organ damage. Male life expectancy shortened by about 20 years compared with normal (if untreated). Prognosis can be improved with early treatment. |
| 12. Prevention | Early diagnosis and early initiation of ERT. Family screening (X-linked inheritance). Identification and follow-up of female carriers. Newborn screening (introduced in some countries). Delaying organ damage by early treatment of hypertension and proteinuria. |
| 13. References | Fabry J. 1898; Anderson W. 1898 and 9 other references |
Fabry disease was reported simultaneously and independently by two physicians in 1898. The German dermatologist Johannes Fabry, under the name "angiokeratoma corporis diffusum," and the British surgeon William Anderson each described patients with the same clinical features. Both reports described angiokeratomatous skin lesions distributed over the whole body as the main symptom, and the disease is also called "Anderson-Fabry disease" after the two authors. Initially this disease was classified as a skin disease, and its systemic nature involving the kidneys, heart, and brain was not fully recognized for decades.
In 1947, Scriba first reported findings of lipid lesions suggesting that this disease is a glycolipid storage disease. The decisive discovery of the molecular mechanism came in 1965, when Roscoe O. Brady and colleagues in the United States found that acid α-galactosidase A (α-Gal A) activity is deficient in the tissues of patients with Fabry disease. With this, Fabry disease was established as a lysosomal storage disease due to a specific enzyme deficiency, and Gb3 (globotriaosylceramide, GL-3) was identified as the main accumulated substrate.
In 1967, the GLA gene was confirmed to be located on the X chromosome, establishing the X-linked mode of inheritance, and in 1986 Bishop, Calhoun, Desnik, et al. cloned the GLA cDNA, laying the foundation for molecular diagnosis. The GLA gene is located at Xq22.1, and since 1987 hundreds to more than a thousand pathogenic variants have been reported.
The turning point in the history of treatment was the approval of enzyme replacement therapy (ERT) in 2001. The recombinant human α-galactosidase A products agalsidase alfa (Replagal, TKT/Shire) and agalsidase beta (Fabrazyme, Genzyme) were approved in Europe and the United States, respectively, opening the era of definitive treatment. In 2016, the non-surgical oral chaperone drug migalastat (Galafold) was approved for patients with specific amenable GLA variants, expanding treatment options. In the 2020s, next-generation ERT agents (pegunigalsidase alfa), RNA therapy (lucerastat), gene therapy, etc. are in the clinical trial stage.
Fabry disease is an X-linked lysosomal storage disease caused by deficient activity of the lysosomal enzyme α-D-galactosidase A (α-galactosidase A, α-Gal A, EC 3.2.1.22) due to pathogenic variants in the GLA gene, located on the long arm of the X chromosome (Xq22.1). At the acidic pH within lysosomes, α-Gal A cleaves the terminal α-galactose residue of Gb3 (globotriaosylceramide, GL-3, CTH)—a glycolipid in which a trisaccharide structure of galactose-galactose-glucose is bound to ceramide—converting it to lactosylceramide. When α-Gal A is deficient, Gb3 cannot be degraded in lysosomes and progressively accumulates in the lysosomes and cytoplasm of cells throughout the body, including the kidneys (glomerular endothelial cells, podocytes, tubular cells), heart (cardiomyocytes, conduction system cells), brain (cerebrovascular endothelial cells, brain neurons), skin, and eyes.
Besides Gb3, lyso-Gb3 (globotriaosylsphingosine, lyso-GL-3) is also an important toxic substrate. Lyso-Gb3 is the form of Gb3 with the N-acyl group removed; it is easier to measure in plasma and urine than Gb3 and is known to directly cause vascular endothelial dysfunction and glomerular cell injury. Lyso-Gb3 is used as a useful biomarker for the diagnosis of Fabry disease and monitoring of treatment response. In addition, galabiosylceramide (Ga2, Gb2) and some blood group antigens (B and P₁ antigens) are also known as related substrates.
More than 1,000 GLA gene variants have been reported to date; missense variants are the most common, followed by splicing variants, nonsense variants, and small deletions/insertions. Residual α-Gal A activity varies by variant type: variants with almost no residual activity produce the classic type presenting in childhood, and variants with some residual activity produce the later-onset type (later-onset, cardiac/renal variant) presenting in adulthood with isolated cardiac or renal involvement.
The GLA gene is located on the long arm of the X chromosome (Xq22.1) and consists of 7 exons spanning 12 kb. The coding sequence is 1,290 bp, and the translated precursor protein is 429 amino acids. The mature α-Gal A enzyme functions as a heterodimer (composed of two monomers forming a homodimer that includes the active site). At the enzyme active site, Asp170 and Asp231 are involved as key catalytic residues, and His257 is important for GLA-specific substrate binding.
The mode of inheritance is X-linked recessive. Because men (XY) have only one X chromosome, if they carry a GLA variant, α-Gal A is essentially deficient (hemizygote) and the disease manifests. Women (XX) are heterozygotes (carriers) with a GLA variant on one X chromosome, and their residual α-Gal A activity is very widely distributed (from the normal range to the level of male patients) depending on the ratio of X chromosome inactivation (lyonization). Therefore, the phenotype in heterozygous women shows a broad spectrum from asymptomatic to severe, similar to men, and as "symptomatic carriers" they need active follow-up and evaluation of treatment indications.
In classic Fabry disease, residual α-Gal A activity is less than 1% in most cases. The later-onset cardiac type (cardiac variant) is observed mainly with the IVS4+919G>A splicing variant and has been reported in people of Asian descent (with a high frequency of 1/1,600 especially in Taiwanese men). A later-onset renal type (renal variant) also exists separately. These later-onset patients are mainly found through newborn screening programs, and in some countries (Taiwan, Italy, Austria, etc.), newborn screening has revealed that the prevalence of later-onset types is 10~40 times higher than expected.
The clinical significance of variants can be checked in the GLA variant database (www.fabry-database.org), and determination of variant pathogenicity and distinguishing later-onset variants from variants of uncertain significance (VUS) are important for treatment decisions.
The prevalence of Fabry disease varies greatly by study method. Traditional clinically based estimates put it at about 1 per 40,000~110,000 male births (about 30,000~50,000 patients worldwide), but newborn dried blood spot (DBS)-based screening studies have reported a much higher combined frequency of classic and later-onset types, at about 1 per 1,500~4,000 births. This difference is because the later-onset types (especially the cardiac type) are often not clinically recognized and the rate of missed diagnosis is high.
It occurs in all ethnic groups worldwide, but a Taiwanese newborn screening study reported a very high male incidence of the later-onset cardiac IVS4+919G>A variant at 1/1,600, suggesting that the frequency of this variant is higher in people of Asian descent than in Western populations. Heterozygous women are about twice as frequent as male patients, so prevalence is even higher when all affected individuals (men + women) are included.
In Korea, accurate epidemiologic data are lacking, but the number of registered Fabry disease patients based on Health Insurance Review & Assessment Service (HIRA) claims data reaches several hundred as of the 2020s, and it is designated as an ultra-rare disease (Special Copayment Reduction V117). Studies screening kidney transplant patients for undiagnosed Fabry disease and screening young stroke patients have raised the possibility that domestic prevalence is higher than previously estimated.
High-risk population screening studies (dialysis patients, patients with unexplained left ventricular hypertrophy, stroke patients under 35 years of age) have reported Fabry disease prevalence of 0.1~1%, so systematic screening is recommended in these populations.
When Gb3 (GL-3) accumulates in lysosomes due to α-Gal A deficiency, systemic organ damage progresses through direct cell injury and secondary inflammatory and fibrotic pathways. The main target cells are vascular endothelial cells (especially in the renal glomeruli, cardiac coronary arteries, and cerebral vessels), vascular smooth muscle cells, renal glomerular podocytes, endothelial cells, and tubular cells, cardiomyocytes, cardiac conduction system cells, and skin keratinocytes and vascular endothelial cells.
At the cellular level, Gb3 accumulation causes lysosomal swelling and dysfunction, mitochondrial dysfunction (oxidative phosphorylation defects, increased reactive oxygen species production), endoplasmic reticulum stress, and blocked autophagic flux. Lyso-Gb3 directly inhibits oxidative stress and NO (nitric oxide) production in vascular endothelial cells, causing endothelial dysfunction, and acts directly toxically on glomerular podocytes, promoting podocyte loss and glomerulosclerosis. In vascular lesions, endothelial dysfunction, smooth muscle cell hypertrophy, and a hypercoagulable tendency (Gb3-related platelet hyperactivation) act in combination to increase the risk of cerebral small vessel disease and thromboembolic stroke.
In the heart, Gb3 accumulates in the lysosomes of cardiomyocytes and conduction system cells, causing increased cell volume, myocardial fibrosis, and abnormal autophagy. As a result, non-obstructive hypertrophic cardiomyopathy (non-obstructive HCM-like phenotype) develops, and the risk of arrhythmias such as atrioventricular block, atrial fibrillation, and ventricular tachycardia also increases. In the kidneys, proteinuria begins with podocyte loss and endothelial injury, followed by progression of glomerulosclerosis and tubulointerstitial fibrosis, leading to chronic kidney disease. It follows a pathologic process similar to diabetic nephropathy, and the rate of GFR decline without treatment is fast, at about 3~5 mL/min per year.
The mechanism of pain is a neuropathy due to lysosomal accumulation of Gb3 in DRG (dorsal root ganglion) neurons of small nerve fibers (small-diameter myelinated Aδ fibers and unmyelinated C fibers), involving ion channel dysfunction (TRPV1, sodium channel Nav1.8), nociceptor sensitization, and central sensitization. Worsening of pain with heat stimuli and physical activity is characteristic.
The clinical symptoms of Fabry disease are highly variable and are classified by involved organ and age of onset. In classic men, the disease begins with neurologic and skin symptoms in childhood to adolescence, followed by progressive involvement of the kidneys, heart, and brain.
Neuropathic pain: The earliest symptom of the classic type, beginning at 5~10 years of age. Burning pain in the distal hands and feet (burning pain, acroparesthesia) is characteristic and is aggravated by fever, hot environments, exercise, and emotional stress. Repeated attacks of severe pain called "Fabry crises" occur. It is due to small fiber neuropathy and is accompanied by reduced cold and warm sensation.
Reduced sweating (hypohidrosis/anhidrosis): Sweating decreases or is absent due to sweat gland dysfunction, and impaired thermoregulation and heat intolerance appear. In some cases, hyperhidrosis paradoxically appears.
Gastrointestinal symptoms: Abdominal pain, diarrhea, nausea, vomiting, and early satiety are common, and the condition is sometimes misdiagnosed as irritable bowel syndrome. Autonomic neuropathy and Gb3 accumulation in the intestinal lining are the cause.
Renal involvement: Begins with proteinuria and leads to progressive GFR decline and chronic renal failure. Without treatment, many patients reach end-stage renal disease (ESRD) in their 30s~50s.
Cardiac involvement: Left ventricular hypertrophy (LVH), non-obstructive hypertrophic cardiomyopathy, atrial fibrillation, atrioventricular block, and heart failure develop. In the later-onset cardiac type, LVH is the main or only symptom.
Brain involvement: Stroke and transient ischemic attack (TIA) occur at a young age (30s~50s). Cerebral white matter lesions are identified on MRI. Tinnitus, sudden hearing loss, and dizziness are also common.
Heterozygous women: Vary from asymptomatic to severe, similar to classic men. Pain, fatigue, depression, renal involvement, cardiac hypertrophy, and stroke are all possible, and diagnosis is easily delayed.
Angiokeratoma: The most characteristic skin sign of Fabry disease, consisting of small dark red to purple angiokeratoma lesions concentrated around the umbilicus, lower abdomen, scrotum, penis, vulva, inner thighs, and buttocks. Each lesion is a non-hemorrhagic papule 1~5 mm in size, visible to the naked eye rather than on slit-lamp examination. It is not a finding specific to Fabry disease, but its distribution pattern provides a diagnostic clue.
Cornea verticillata: On slit-lamp examination, whorl (vortex)-shaped yellowish-brown lines are observed within the corneal epithelium. These result from Gb3 accumulation in corneal epithelial cells due to α-Gal A deficiency and do not affect vision. Because similar findings can occur with some drugs such as amiodarone and chloroquine, a medication history must be checked.
Cardiac findings: Echocardiography shows increased left ventricular wall thickness (LVH), increased left ventricular mass index, and diastolic dysfunction. The ECG may show a shortened PR interval, ventricular hypertrophy, bundle branch block, and atrioventricular block. On cardiac MRI (CMR), reduced native T1 signal reflecting Gb3 accumulation (basal inferolateral wall region) and gadolinium enhancement (myocardial fibrosis) are known as the characteristic CMR pattern of Fabry disease.
Renal findings: Urinalysis shows proteinuria (beginning with albuminuria), microscopic hematuria, and lipid-laden tubular cells. On electron microscopy of renal biopsy, concentric lamellar membranous inclusions in lysosomes of glomerular and tubular cells—"zebra bodies"—are the specific pathologic finding of Fabry disease.
Brain MRI: Multifocal hyperintense lesions of the cerebral white matter are observed on T2/FLAIR. Involvement of the occipital lobes, thalamus, and basal ganglia is characteristic. T1 hyperintensity of the posterior thalamic pulvinar (the so-called "pulvinar sign") is a relatively specific MRI finding of Fabry disease.
The delay to diagnosis of Fabry disease has been reported to average 10~15 years, underscoring the importance of systematic screening.
Newborn screening (DBS): Measuring α-Gal A activity in dried blood spots by a fluorogenic substrate method or tandem mass spectrometry (LC-MS/MS) is technically established. It is included in expanded newborn screening panels in Taiwan, Italy, Austria, and some US states, and shows high sensitivity mainly in males. In females, enzyme activity is in the intermediate range, so false negatives are possible, and GLA gene analysis is an essential complementary test.
High-risk group screening: Systematic screening for Fabry disease is recommended in the following clinical populations. (1) Patients with unexplained hypertrophic cardiomyopathy (LVH)—to exclude a cause treatable with ERT; (2) patients with stroke or TIA under 35~40 years of age; (3) patients with unexplained chronic kidney disease or on dialysis; (4) patients with unexplained small fiber neuropathy; (5) all family members of patients with Fabry disease.
Plasma/urine lyso-Gb3 measurement: Plasma or urine lyso-Gb3 (LC-MS/MS) has high diagnostic sensitivity in both men and women, and abnormal findings are observed more consistently especially in heterozygous women whose α-Gal A activity is in the normal range. It is also useful for monitoring treatment response.
In principle, Fabry disease is confirmed by combining measurement of α-Gal A enzyme activity with GLA gene analysis.
Diagnosis in men: Markedly reduced leukocyte (or plasma) α-Gal A activity, from less than 1% to less than 5% of the normal control range, strongly suggests classic or later-onset Fabry disease. DBS activity measurement is used for screening purposes. When enzyme activity is reduced, it must be confirmed by GLA gene analysis, and identification of a pathogenic variant is essential for treatment decisions. Substrate-specific measurement (using 4-MU-α-D-Gal) is needed to differentiate from α-galactosidase B (α-Gal B, product of the NAGA gene).
Diagnosis in women: In heterozygous women, α-Gal A activity may overlap with the normal range, so diagnosis or exclusion by enzyme activity alone is impossible. Therefore, GLA gene analysis is the key to confirmation in women. Even if enzyme activity is normal, gene analysis is performed when there is a family history, clinical symptoms, or elevated lyso-Gb3.
Lyso-Gb3 measurement: LC-MS/MS measurement of plasma and urine lyso-Gb3 is useful as a diagnostic aid in both men and women and is also used as a biomarker for evaluating treatment response. In classic patients, lyso-Gb3 is markedly elevated (tens to hundreds of times the upper limit of normal in plasma), while in later-onset types a mild elevation is seen.
Histopathology: "Zebra bodies" (concentric lamellar intracytoplasmic inclusions) can be identified on electron microscopy of renal biopsy. Gb3 inclusions in vascular endothelial cells and sweat gland cells are also observed on skin biopsy. These findings play a supporting role before confirmation.
Definitive treatment has been available for Fabry disease since 2001. The two pillars of treatment are enzyme replacement therapy (ERT) and a pharmacologic chaperone (migalastat), combined with adjunctive treatment to protect organ function.
Enzyme replacement therapy (ERT):
Both agents have been proven to reduce plasma and tissue Gb3, reduce lyso-Gb3, relieve pain, stabilize renal function (when started early), and inhibit progression of cardiac hypertrophy. Because ERT cannot reverse already advanced glomerulosclerosis, myocardial fibrosis, or cerebral ischemic lesions, early initiation before irreversible organ damage is very important.
Migalastat (Galafold): Oral pharmacologic chaperone. In specific GLA variants (amenable mutations), it stabilizes misfolded α-Gal A protein and restores normal trafficking to lysosomes. 123 mg orally every other day. Whether a variant is amenable is confirmed by a cell assay-based database (GLP-certified amenability assay) or by evaluation at a specialized Fabry disease institution. More convenient (oral) than ERT, but not applicable to all patients.
Adjunctive therapy: ACE inhibitors or ARBs are given to reduce proteinuria and preserve renal function. SGLT2 inhibitors and MRAs (mineralocorticoid receptor antagonists) are added for proteinuria reduction and renal protection. Antiarrhythmics for cardiac arrhythmias, standard heart failure treatment for heart failure, and antithrombotics (antiplatelet agents or anticoagulants) for stroke prevention are given concurrently. Carbamazepine, gabapentin, and mexiletine are used for pain management, and guidance on environmental control for impaired thermoregulation is needed.
Treatments in clinical research: Pegunigalsidase alfa (Elfabrio, Protalix/Chiesi) received FDA approval in 2023, adding a new ERT option. Lucerastat (substrate reduction therapy), gene therapy (AAV-based GLA delivery), etc. are in clinical research.
In the natural course of Fabry disease, the life expectancy of untreated classic male patients is shortened by about 15~20 years compared with the general population, and the main causes of death are renal failure, heart disease (heart failure, arrhythmias), and stroke. In the era before ERT, the mean age at death of male patients was in the 40s~50s.
The prognostic benefits of early ERT initiation can be summarized as follows. Starting ERT before symptom onset or at an early stage of renal damage (glomerulosclerosis less than 20%, mild tubulointerstitial fibrosis) is effective in stabilizing renal function and delaying progression to renal failure. In contrast, when GFR has already fallen to the level of < 30 mL/min/1.73m², the effect of ERT is limited. In terms of cardiac hypertrophy, early ERT inhibits increases in left ventricular mass and progression of cardiac fibrosis, and may also contribute to reducing the risk of ventricular arrhythmias and sudden death.
The prognosis of heterozygous women varies greatly depending on the degree of skewed X inactivation, and even in asymptomatic women cardiac and renal involvement can progress and end-stage organ damage can develop. Regular follow-up of women is essential. In later-onset (cardiac type) men as well, the risks of heart failure and arrhythmias increase if treatment initiation is delayed, so early diagnosis and determination of treatment indications are important.
Both aspects of Fabry disease prevention—fundamental prevention (genetic prevention) and prevention of organ damage (organ protection)—are important.
Genetic prevention: When a woman heterozygous for a GLA variant (carrier) is identified, genetic counseling before planning pregnancy, prenatal diagnosis (analysis of fetal α-Gal A activity and the GLA gene by CVS or amniocentesis), and preimplantation genetic testing (PGT-M) are offered as options. With X-linked inheritance, 50% of sons are affected and 50% of daughters are heterozygotes.
Family screening: After a patient with Fabry disease is identified, screening is recommended for all family members (siblings, children, nephews and nieces, etc.). Especially for sisters and daughters, heterozygosity is determined by GLA gene analysis, and heterozygous women undergo regular follow-up of cardiac, renal, and neurologic function.
Newborn screening: In some countries (Taiwan, Italy, Austria, some US states), DBS-based newborn screening programs allow early detection followed by proactive follow-up and timely initiation of ERT. Expansion of newborn screening is also being discussed in Korea.
Prevention of organ damage: In already diagnosed patients, early initiation of ERT, control of proteinuria with ACE inhibitors/ARBs, achieving a blood pressure target below 130/80 mmHg, adding SGLT2 inhibitors, correcting dyslipidemia, smoking, and obesity, temperature management, and regular follow-up (annual renal, cardiac, neurologic, ophthalmologic, and otolaryngologic evaluation) are important to slow the progression of organ damage.